PDS Biotechnology Corporation

Good morning, ladies and gentlemen, and welcome to PDS Biotech's third quarter 2024 results and clinical strategy update conference call. All participants are currently in listen-only mode. Following the formal presentation, we will open up the call for question and answer session. I would now like to turn the conference over to Tom Johnson with LifeSciAdvisors. Please go ahead, sir.

Thank you, Operator, and good morning, everyone. Welcome to PDS Biotech's third quarter 2024 results and clinical strategy update call. I'm joined on the call today by the following members of the company's management team. Dr. Frank Beto-Addo, Chief Executive Officer, Dr. Kurt Shepard, Chief Medical Officer, and Lars Bosgaard, Chief Financial Officer. Dr. Beto-Addo will begin with an overview of the company's recent interactions with investors, investigators, and others regarding its clinical development plans. Mr. Boesgaard will review our financial results for the third quarter, and Dr. Shepherd will then join the call to help address questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with the cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10Q, an annual report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now, I'd like to turn the call over to Dr. Beto Addo. Frank? Thank you, Tom, and good morning, everyone.